Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | STAT3 | P40763 | 1/20 | 0.69 |
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | CCR5 | P51681 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | IDE | P14735 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978122 | 0.89 | SMN1; SMN2 (0.72) | MEN1KMT2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL17540905 | 0.89 | MEN1 (0.63) | MEN1KMT2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL9977994 | 0.84 | MEN1 (0.87) | MEN1KMT2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL9977992 | 0.84 | MEN1 (0.73) | MEN1KMT2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL9978124 | 0.82 | MEN1 (1.00) | MEN1KMT2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL4019375 | 0.82 | ALDH1A1 (0.56) | MEN1KMT2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL19422869 | 0.81 | MEN1 (0.81) | MEN1KMT2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL19418973 | 0.81 | USP2 (0.62) | MEN1KMT2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL9977996 | 0.81 | MEN1 (0.83) | MEN1KMT2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL23536551 | 0.81 | TSHR (0.66) | MEN1KMT2AMAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | EIGER BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2016032569-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | CELLADON CORPORATION (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | ATP2A1, ATP2A3, ATP2A2 | MEN1 4199/4885KMT2A 4359/4885MAPK1 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.